Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retinal vein thrombosis06.10.01.003; 24.01.07.0020.000482%Not Available
Rhinorrhoea22.12.03.0210.015600%
Rosacea23.02.08.0010.001640%Not Available
Rotator cuff syndrome12.01.07.018; 15.01.08.0020.000723%
Scab23.03.03.0040.002580%Not Available
Sciatica17.10.03.001; 15.10.01.0010.004461%Not Available
Seborrhoeic dermatitis23.03.04.0180.000820%Not Available
Second primary malignancy16.16.01.014--
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Serum sickness12.02.08.004; 10.01.03.0040.000241%
Sinus congestion22.04.06.0010.005401%Not Available
Skin atrophy23.01.05.0010.002049%
Skin cancer23.08.02.002; 16.03.02.0020.002049%Not Available
Skin depigmentation23.05.02.0020.001350%Not Available
Skin disorder23.03.03.0070.010922%Not Available
Skin exfoliation23.03.07.0030.013309%Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Skin wrinkling23.01.03.0010.000530%Not Available
Sleep talking19.02.03.005; 17.15.02.0030.000530%Not Available
Sluggishness08.01.01.0040.004099%Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.001085%Not Available
Swelling08.01.03.0150.045040%Not Available
Swelling face10.01.05.018; 08.01.03.100; 23.04.01.0180.029657%Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Teratogenicity12.03.01.032; 03.02.01.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.0060.050393%Not Available
Thyroid disorder05.02.01.0020.003713%Not Available
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 16 Pages